GlassScriptPhysician profile
Raymond M Pongonis
NPI 1023274792
$12,104.37
in general payments reported to CMS, 2019-2025
22 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,583 · 2020: $754 · 2021: $1,090 · 2022: $1,543 · 2023: $1,460 · 2024: $1,647 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,072 · Education: $62.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,071.97 |
| Education | $62.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $3,240.60 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,376.70 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $1,880.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,185.29 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $897.36 | 2019-2025 | Dupixent |
| Genzyme Corporation | $497.97 | 2019-2025 | |
| Genentech USA, INC. | $486.48 | 2019-2025 | Xolair |
| Amgen INC. | $381.11 | 2021-2025 | Tezspire |
| Kaleo, INC. | $340.64 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.17 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $157.63 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $125.03 | 2019-2023 | Airduo Digihaler |
| Sanofi-Aventis U.S. LLC | $63.89 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $62.85 | 2020-2021 | |
| Pfizer INC. | $60.23 | 2019-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $47.82 | 2024-2025 | Opzelura |
| Hikma Pharmaceuticals USA | $36.58 | 2022-2024 | Ryaltris |
| Phadia US INC. | $32.39 | 2023-2025 | Immunocap |
| Lilly USA, LLC | $27.12 | 2025 | Taltz, Ebglyss |
| Biocryst US Sales Co., LLC | $16.83 | 2022 | |
| Alk-Abello, INC | $12.99 | 2020 | |
| Merck Sharp & Dohme LLC | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Pongonis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.